Biotech News

HUTCHMED to Announce 2025 Final Results

HUTCHMED (HCM)HUTCHMEDCommercial

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/ . The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .

CONTACTS

Investor Enquiries+852 2121 8200 / [email protected]
Media Enquiries
FTI Consulting –+44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]
Panmure LiberumNominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500
CavendishJoint Broker
Geoff Nash / Nigel Birks+44 20 7220 0500
Deutsche NumisJoint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000

Related news

HUTCHMED

China-Originated Oncology Company HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities. Commercial...

Recent company news

Stock data

Close
12.63 USD
Market cap
1.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States